← Eichor
Study identifier: NCT06944457 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor

Condition: Cancer · Solid Tumor Cancer · Biomarkers  ·  Sponsor: Pharosgen Co.,Ltd

PhasePhase 1
Planned participants24
Who can joinAll sexes, 19 Years to 75 Years
Healthy volunteersNo

About this study

A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor

This description comes directly from the study's public registry record.

Talk to the study team

Geon Tae Park, Bachelor's degree  ·  82-10-2704-8955  ·  gtpark@pharosgen.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

Asan Medical CenterSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06944457